CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Regan, Meredith M × Leyland-Jones, Brian Bouzyk, Mark Pagani, Olivia Tang, Weining Kammler, Roswitha Dell'orto, Patrizia Biasi, Maria Olivia Thürlimann, Beat Lyng, Maria B Ditzel, Henrik J Neven, Patrick Debled, Marc Maibach, Rudolf Price, Karen N Gelber, Richard D Coates, Alan S Goldhirsch, Aron Rae, James M Viale, Giuseppe Breast International Group (BIG) 1-98 Collaborative Group #
Oxford University Press
Journal of the National Cancer Institute vol:104 issue:6 pages:441-451
Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms.